Akzo N.v.

Akzo Nobel N.v.

Per Immune Holdings, Inc.

Intracel Resources LLC

Intracel Holdings LLC

Nicholas Pomato

Reinhard Bredehorst

Martin V Haspel

Richard P McCabe

Michael G Hanna, Jr

Carl-Wilhelm Ernst Vogel

Chong-Ho Kim

Janet H Ransom

Ebo S Bos

Gregory Alan Hawkins

Joachim Thiem

Herbert C Hoover, Jr

Oliver Scheel

Sandra M Butler

Michael L Berman

Gregory A Hawkins

Ebo Bos

This invention providesantitoxin compositions and methods of production, and methods of treating animals and humans prophylactically and also those suspected of having contacted botulism toxin. Theantitoxin is prepared by inoculating an animal with a monovalenttoxoid and toxin. The animal's plasma is collected and purified at a high pH by affinity chromatography. The resulting monovalent immunoglobulins are de-speciated by digestion with pepsin. Monovalent antitoxins for all sevenserotypes are then combined to produce a high titered heptavalentantitoxin composition.

Botulinum antitoxin compositions and methods

This invention relates to methods of removing bioburden from an aggregate of cells to obtain sterile cells that remain viable and immunogenic for the production of vaccines. This invention further relates to a method of eliciting an immune response to prevent a recurrence of metastases that involves preparing and administering a sterile vaccine derived from solid tumors. The vaccine is prepared by excising a solid tumor from a cancer patient, digesting the tumor cells with an enzyme to obtain dissociated cells, irradiating the dissociated cells to render the cells non-tumorigenic, and sterilizing the cells.

Sterile immunogenic non-tumorigenic tumor cell compositions and methods

A method for in-vivo targeting a functional moiety in a patient by administering a targeting moiety coupled to an affinity component, wherein the targeting moiety has affinity for binding sites in a target area, and administering a binding partner to the affinity component coupled to a functional moiety to localize the functional moiety in the target area. Preferably the targeting moiety is an antibody and the functional moiety is a radiometal when performing in vivo imaging or therapy. The affinity component may be a novel methotrexate analog. Preferably, the affinity component is thermo-stabilized.

In vivo binding pair pretargeting

This invention relates to the epitopes to which monoclonal antibody 88BV59 and antibody 16.88 react. These antibodies were produced by B-cell lines derived from B-cells of cancer patients actively immunized with autologous tumor antigens. Both epitopes are found on the same antigen in tumor tissue. These epitopes can be used in both diagnostic procedures and therapy for human cancers.

Tumor associated epitope

A method for in-vivo targeting a functional moiety in a patient by administering a targeting moiety coupled to an affinity component, wherein the targeting moiety has affinity for binding sites in a target area, and administering a binding partner to the affinity component coupled to a functional moiety to localize the functional moiety in the target area. Preferably the targeting moiety is an antibody and the functional moiety is a radiometal when performing in vivo imaging or therapy. The affinity component may be a novel methotrexate analog.

The present invention is directed to a new process for the production of chitin oligomers, including fragmentation, partial hydrolysis and recovery. This process produces high yields, especially of higher (tetra- to deca-) chitin oligomers.

High yield preparation of dimeric to decameric chitin oligomers

CTAA 81AV78, the antigen recognized by human monoclonal antibody 81AV78

The present invention comprises the epitope recognized by the human monoclonal antibody 28A32, the human tumor antigen containing this epitope, which we have identified, isolated and characterized, and human MCA 28A32. The invention also relates to the use of antibodies to the antigen containing this epitope for diagnosis and monitoring of treatment of cancer and to the use of this antigen in the preparation of vaccines to elicit an immune response similar to that obtained against tumor cells containing this epitope.

CTAA 28A32, the antigen recognized by MCA 28A32

A method for site-specific in-vivo activation of a prodrug in an animal using an activator-targeting moiety conjugate to localize an activator at a predetermined site of use and a prodrug compound that is converted to an active drug in the presence of the activator. In the preferred embodiment, the targeting moiety, the activator, and the prodrug demonstrate little or no immunogenicity in the animal being treated. The targeting moiety is relatively specific for binding to the target tissue than to non-target tissue. The activator is not found or present in only small amounts in circulation or in non-target tissue, does not have a substrate for its activity in circulation or in non-target tissue, can be linked to the targeting moiety, and is capable of converting the prodrug to an active drug. The prodrug is selected for its ability to exert a cytotoxic activity on the target tissue after conversion by the activator.

Site specific in vivo activation of therapeutic drugs

The present invention comprises the epitope recognized by the human monoclonal antibody 16-18, the human tumor antigen containing this epitope, which we have identified, isolated and characterized, and anti-idiotypic antibodies to human MCA 16-88, which comprise the same epitope. The invention also relates to the use of antibodies to the antigen containing this epitope for diagnosis and monitoring of treatment of cancer and to the use of this antigen in the preparation of vaccines to elicit an immune response similar to that obtained against tumor cells containing this epitope.

Antigen recognized by MCA 16-88

Leukoregulin is identified, a biologically active lymphokine of molecular weight of about 120,000 to 140,000, with subunits of about 30,000 to 35,000, having the isoelectric focusing pH's of between 4.8 and 5.5 or between 7.5 and 8.3, which has the ability to regulate tumor cell physiology and growth without affecting the growth of normal cells. Methods for stimulating its production by monouclear cells, methods for its isolation and purification, and methods for its therapeutic uses are also disclosed.

Growing community of inventors

Frederick, MD, United States of America

Nicholas Pomato